Home
ViaCyte

ViaCyte Market Share Analysis for May 2026

viacyte is a regenerative medicine company focused on the discovery, development & commercialization of novel cell replacement therapies to treat diabetes.

Health > Biotechnology and Pharmaceuticals

Domainviacyte.com

Year Founded1999

Employees51 - 200

Annual Revenue$15M - $25M

ViaCyte

ViaCyte (including company regionals)

viacyte.com

See more website traffic and engagement information

ViaCyte Revenue up to May 2026 is 15M - 25M

revenue generated by ViaCyte top domains

ViaCyte top domains revenue over 3 years

Revenue for ViaCyte top domains

viacyte.com15M - 25M

See more with Sales Intelligence

Total visits to ViaCyte's top domains

Understand ViaCyte market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in ViaCyte's top domains

Analyze ViaCyte engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on ViaCyte's top domains

See how ViaCyte keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

ViaCyte top competitors by domain

Top similar sites in May 2026, ranked by their affinity

oncomed.comCompany NameOncoMed PharmaceuticalsEmployees51 - 200HQUnited States, California, Redwood CityAnnual revenue$25M - $50MTotal visits47Health > Biotechnology and Pharmaceuticals

Top technologies used by ViaCyte

These are the website technologies, by industry, used by ViaCyte top domains

Payment & Currencies (7)

PayPal

Widget (6)

Twemoji

eCommerce (4)

USPS

Advertising (3)

DoubleClick

More Technologies

11

See all

News & Signals from ViaCyte

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsT1D Fund invested into ViaCyte Media Contact on Jul 1st '22.* The T1D Fund also invested in ViaCyte, which was acquired by Vertex in 2022.

NewsJaiman leaves ViaCyte Media Contact as Vice President.Prior to joining Aardvark, Dr. Jaiman was Vice President at Vertex Pharmaceuticals and Chief Medical Officer of ViaCyte where she developed novel approaches in cell therapy.

NewsViaCyte Media Contact partnered with CRISPR Therapeutics on Sep 17th '18.As per the original agreement, which was signed in September 2018 between ViaCyte and CRISPR, the biotechs would combine ViaCyte's stem cell expertise with CRISPR's gene editing technologies to develop a potential beta-cell replacement product that could help patients produce their own insulin without inducing an immune reaction.